KRAS and hepatocellular carcinoma: As an example of the distinction between the PLC types, oncogenic RAS mutations are rare in HCC despite the general activation of RAS–MAPK signaling (Calvisi et al. 2006), whereas ICC frequently harbors oncogenic KRAS mutations, particularly at codon 12 (Zou et al. 2014).